ClinicaI Reversible Myelopathy in T-Cell Lymphoblastic Lymphoma Treated with Nelarabine and Radiotherapy: Report of a Case and Review of Literature of an Increasing Complication

Main Article Content

Maria Chiara Tisi
Giuseppe Ausoni
Maria Gabriella Vita
Tommaso Tartaglione
Mario Balducci
Luca Laurenti
Patrizia Chiusolo
Stefan Hohaus
Simona Sica


T Lymphoblastic Lymphoma, Nelarabine, Myelopathy


To date, eleven cases of irreversible neurological defects in T- ALL patients treated with nelarabine have been described in the last 4 years, seven of these after stem cell transplantation (SCT) for T Lymphoblastic Lymphoma (T-LBL). Most of patients had an unfavorable outcome or irreversible damage.

We report the case of a 41-year-old woman suffering from T-LBL who presented severe but reversible myelopathy after nelarabine based treatment and mediastinum radiotherapy, and we perform a review of literature.


Download data is not yet available.

Abstract 1975
PDF Downloads 731
HTML Downloads 1559
Fig 1 Downloads 0
Tab I Downloads 0
Cover Letter Downloads 0


[1] Hoelzer D, Gökbuget N, Digel W, Faak T, Kneba M, Reutzel R, Romejko-Jarosinska J, Zwolinski J, Walewski J. Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia. Blood 2002 ;99:4379-85.

[2] Cheson BD. Role of functional imaging in the management of lymphoma. J Clin Oncol 2011 ;29:1844-54.

[3] Common terminology criteria for Adverse Events (CTCAE); v4.03: June 14, 2010. National Institute of Health; National Cancer Institute.

[4] Reilly KM, Kisor DF. Profile of nelarabine: use in the treatment of T-cell acute lymphoblastic leukemia. Onco Targets Ther 2009 ; 2:219-28.

[5] Papayannidis C, Iacobucci I, Abbenante MC, Curti A, Paolini S, Parisi S, Baccarani M, Martinelli G. Complete paraplegia after nelarabine treatment in a T-cell acute lymphoblastic leukemia adult patient. Am J Hematol 2010 ;85: 608.

[6] Forcade E, Leguay T, Vey N, Baruchel A, Delaunay J, Robin M, Socié G, Dombret H, Peffault de Latour R, Raffoux E. Nelarabine for T cell acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation: an opportunity to improve survival. Biol Blood Marrow Transplant 2013 ;19: 1124-6.

[7] Kawakami M, Taniguchi K, Yoshihara S, Ishii S, Kaida K, Ikegame K, Okada M, Watanabe S, Nishina T, Hamada H, Nakagawa M, Ogawa H. Irreversible neurological defects in the lower extremities after haploidentical stem cell transplantation: possible association with nelarabine. Am J Hematol 2013 ; 88: 853-7.

[8] Gollard RP, Selco S. Irreversible myelopathy associated with nelaribine in T-cell acute lymphoblastic leukemia. J Clin Oncol 2013 ;31:327-31.

[9] Hartz B, Löbel U, Hagel C, Escherich G. Fatal neurological side-effects with necrosis of spinal cord following nelarabine treatment in a child with relapsed T-cell acute lymphoblastic leukemia. Am J Hematol 2013 ;88:1096-7.

[10] Ngo D, Patel S, Kim EJ, Brar R, Koontz MZ. Nelarabine neurotoxicity with concurrent intrathecal chemotherapy: Case report and review of literature. J Oncol Pharm Practic 2014 ;0:1–5.